Literature DB >> 31561363

Race, APOEɛ4, and Long-Term Cognitive Trajectories in a Biracial Population Sample.

Kumar B Rajan1, Elizabeth A McAninch2, Robert S Wilson3,4,5, Jennifer Weuve6, Lisa L Barnes3,4,5, Denis A Evans2.   

Abstract

BACKGROUND: The association of the APOEɛ4 allele with incident Alzheimer's dementia is higher among European Americans (EAs) than African Americans (AAs), but similar for the rate of cognitive decline.
OBJECTIVE: To examine the racial differences in the association of the APOEɛ4 allele with incident Alzheimer's dementia and cognitive decline.
METHODS: Using a population-based sample of 5,117 older adults (66% AAs and 63% females), we identified cognitive trajectory groups from a latent class mixed model and examined the association of the APOEɛ4 allele with these groups.
RESULTS: The frequency of the APOEɛ4 allele was higher among AAs than EAs (37% versus 26%). Four cognitive trajectories were identified: slow, mild, moderate, and rapid. Overall, AAs had a lower baseline global cognition than EAs, and a higher proportion had rapid (7% versus 5%) and moderate (20% versus 15%) decline, but similar mild (44% versus 46%), and lesser slow (29% versus 34%) decline compared to EAs. Additionally, 25% of AAs (13% of EAs) with mild and 5% (<1% of EAs) with slow decline were diagnosed with incident Alzheimer's dementia. The APOEɛ4 allele was associated with higher odds of rapid and moderate decline compared to slow decline among AAs and EAs, but not with mild decline.
CONCLUSIONS: AAs had lower cognitive levels and were more likely to meet the cognitive threshold for Alzheimer's dementia among mild and slow decliners, explaining the attenuated association of the ɛ4 allele with incident Alzheimer's dementia among AAs.

Entities:  

Keywords:  Alzheimer’s disease; Apolipoproteins E; cognitive aging; race relations

Year:  2019        PMID: 31561363      PMCID: PMC6914259          DOI: 10.3233/JAD-190538

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  37 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Christopher D Corcoran; Maria C Norton; Peter V Rabins; Martin I Steinberg; Joann T Tschanz; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

3.  Cognitive activity and incident AD in a population-based sample of older persons.

Authors:  R S Wilson; D A Bennett; J L Bienias; N T Aggarwal; C F Mendes De Leon; M C Morris; J A Schneider; D A Evans
Journal:  Neurology       Date:  2002-12-24       Impact factor: 9.910

4.  Cognitive activity in older persons from a geographically defined population.

Authors:  R S Wilson; D A Bennett; L A Beckett; M C Morris; D W Gilley; J L Bienias; P A Scherr; D A Evans
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  1999-05       Impact factor: 4.077

5.  Predictors of combined cognitive and physical decline.

Authors:  Hal H Atkinson; Matteo Cesari; Stephen B Kritchevsky; Brenda W J H Penninx; Linda P Fried; Jack M Guralnik; Jeff D Williamson
Journal:  J Am Geriatr Soc       Date:  2005-07       Impact factor: 5.562

6.  Trajectories of cognitive decline in Alzheimer's disease.

Authors:  Patricia A Wilkosz; Howard J Seltman; Bernie Devlin; Elise A Weamer; Oscar L Lopez; Steven T DeKosky; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2009-09-28       Impact factor: 3.878

7.  Factors related to racial differences in late-life level of cognitive function.

Authors:  Robert S Wilson; Kumar B Rajan; Lisa L Barnes; Jennifer Weuve; Denis A Evans
Journal:  Neuropsychology       Date:  2016-05-05       Impact factor: 3.295

8.  Design of the Chicago Health and Aging Project (CHAP).

Authors:  Julia L Bienias; Laurel A Beckett; David A Bennett; Robert S Wilson; Denis A Evans
Journal:  J Alzheimers Dis       Date:  2003-10       Impact factor: 4.472

9.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

10.  Cognitive lifestyle jointly predicts longitudinal cognitive decline and mortality risk.

Authors:  Riccardo E Marioni; Cecile Proust-Lima; Helene Amieva; Carol Brayne; Fiona E Matthews; Jean-Francois Dartigues; Helene Jacqmin-Gadda
Journal:  Eur J Epidemiol       Date:  2014-02-28       Impact factor: 8.082

View more
  10 in total

1.  Rates of Cognitive Decline in 100 Patients With Alzheimer Disease.

Authors:  Monica Miyakawa-Liu; Amy K Feehan; Shannon Pai; Julia Garcia-Diaz
Journal:  Ochsner J       Date:  2022

2.  Disparity and Multimorbidity in Heart Failure Patients Over the Age of 80.

Authors:  Anna Blach; Amanda Pangle; Gohar Azhar; Jeanne Wei
Journal:  Gerontol Geriatr Med       Date:  2022-05-12

3.  TOMM40-APOE haplotypes are associated with cognitive decline in non-demented Blacks.

Authors:  Kacie D Deters; Elizabeth C Mormino; Lei Yu; Michael W Lutz; David A Bennett; Lisa L Barnes
Journal:  Alzheimers Dement       Date:  2021-02-13       Impact factor: 21.566

4.  Race, APOE genotypes, and cognitive decline among middle-aged urban adults.

Authors:  May A Beydoun; Jordan Weiss; Hind A Beydoun; Sharmin Hossain; Ana I Maldonado; Botong Shen; Michele K Evans; Alan B Zonderman
Journal:  Alzheimers Res Ther       Date:  2021-06-30       Impact factor: 6.982

5.  Associations between race, APOE genotype, cognition, and mortality among urban middle-aged white and African American adults.

Authors:  Jordan Weiss; Sharmin Hossain; Ana I Maldonado; Botong Shen; Hind A Beydoun; Mika Kivimaki; Michele K Evans; Alan B Zonderman; May A Beydoun
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.996

6.  Dementia risk in a diverse population: A single-region nested case-control study in the East End of London.

Authors:  Phazha L K Bothongo; Mark Jitlal; Eve Parry; Sheena Waters; Isabelle F Foote; Cameron J Watson; Jack Cuzick; Gavin Giovannoni; Ruth Dobson; Alastair J Noyce; Naaheed Mukadam; Jonathan P Bestwick; Charles R Marshall
Journal:  Lancet Reg Health Eur       Date:  2022-02-11

7.  Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease.

Authors:  Jaeho Kim; Sook-Young Woo; Seonwoo Kim; Hyemin Jang; Junpyo Kim; Jisun Kim; Sung Hoon Kang; Duk L Na; Juhee Chin; Liana G Apostolova; Sang Won Seo; Hee Jin Kim
Journal:  Alzheimers Res Ther       Date:  2021-06-14       Impact factor: 6.982

8.  Genetic risk, adherence to a healthy lifestyle, and cognitive decline in African Americans and European Americans.

Authors:  Klodian Dhana; Lisa L Barnes; Xiaoran Liu; Puja Agarwal; Pankaja Desai; Kristin R Krueger; Thomas M Holland; Shannon Halloway; Neelum T Aggarwal; Denis A Evans; Kumar B Rajan
Journal:  Alzheimers Dement       Date:  2021-07-26       Impact factor: 16.655

9.  Interaction of APOE4 alleles and PET tau imaging in former contact sport athletes.

Authors:  Anna Vasilevskaya; Foad Taghdiri; Charles Burke; Apameh Tarazi; Seyed Ali Naeimi; Mozghan Khodadadi; Ruma Goswami; Christine Sato; Mark Grinberg; Danielle Moreno; Richard Wennberg; David Mikulis; Robin Green; Brenda Colella; Karen D Davis; Pablo Rusjan; Sylvain Houle; Charles Tator; Ekaterina Rogaeva; Maria C Tartaglia
Journal:  Neuroimage Clin       Date:  2020-02-13       Impact factor: 4.881

10.  The Impact of the COVID-19 Pandemic on Alzheimer's Disease and Other Dementias.

Authors:  Jinghuan Gan; Shuai Liu; Hao Wu; Zhichao Chen; Min Fei; Junying Xu; Yuchao Dou; Xiaodan Wang; Yong Ji
Journal:  Front Psychiatry       Date:  2021-07-14       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.